RESUMO
Presentation of non-aversive light stimuli for several seconds was found to reliably induce locomotor activation and exploratory-like activity. Light-induced locomotor activity (LIA) can be considered a convenient simple model to study sensory-motor activation. LIA was previously shown to coincide with serotonergic and dopaminergic activation in specific cortical areas in freely moving and anesthetized animals. In the present study we explore the neuropharmacology of LIA using a receptor antagonist/agonist approach in rats. The non-selective 5-HT2-receptor antagonist ritanserin (1.5-6 mg/kg, i.p.) dose-dependently reduced LIA. Selective antagonism of either the 5-HT2A-receptor by MDL 11,939 (0.1-0.4 mg/kg, i.p.), or the 5-HT2C-receptor by SDZ SER 082 (0.125-0.5 mg/kg, i.p.), alone or in combination, had no significant influence on LIA. Also the selective 5-HT1A-receptor antagonist, WAY 100635 (0.4 mg/kg, i.p.) did not affect LIA. Neither did the preferential dopamine D2-receptor antagonist, haloperidol (0.025-0.1 mg/kg, i.p.) nor the D2/D3-receptor agonist, quinpirole (0.025-0.5 mg/kg, i.p.) affect the expression of LIA. However, blocking the glutamatergic NMDA-receptor with phencyclidine (PCP, 1.5-6 mg/kg, i.p.) dose-dependently reduced LIA. This effect was also observed with ketamine (10 mg/kg, i.p.). These findings suggest that serotonin and dopamine receptors abundantly expressed in the cortex do not mediate light-stimulus triggered locomotor activity. PCP and ketamine effects, however, suggest an important role of NMDA receptors in LIA.
Assuntos
Dopaminérgicos/farmacologia , Fármacos Atuantes sobre Aminoácidos Excitatórios/farmacologia , Luz , Atividade Motora/efeitos dos fármacos , Atividade Motora/efeitos da radiação , Antagonistas da Serotonina/farmacologia , Animais , Relação Dose-Resposta a Droga , Haloperidol/farmacologia , Indóis/farmacologia , Ketamina/farmacologia , Masculino , Naftiridinas/farmacologia , Fenciclidina/farmacologia , Estimulação Luminosa , Piperazinas/farmacologia , Piperidinas/farmacologia , Piridinas/farmacologia , Quimpirol/farmacologia , Ratos Wistar , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Receptores de N-Metil-D-Aspartato/metabolismo , Ritanserina/farmacologiaRESUMO
Neurokinin(3) receptors (NK(3)-Rs) have been implicated in psychomotor activity and reinforcement mechanisms. Recently, we showed that NK(3)-R antagonism blocked the psychostimulant properties of cocaine both in rats and in primates. Here, using in vivo microdialysis in the nucleus accumbens (NAc) of freely moving rats, we investigated the effect of the NK(3)-R agonist senktide (0.2 and 0.4 mg/kg s.c.) on the cocaine-evoked increase in dopamine. Cocaine (10 mg/kg i.p.) increased dopamine levels to 404 and 480% of baseline in the core and shell of the NAc, respectively. Pretreatment with senktide at a dose of 0.2 mg/kg potentiated this effect to 666 (core) and 869% (shell) of baseline, without having any effect on dopamine when given alone. Behavioural measurements revealed that 0.2 mg/kg senktide also potentiated the cocaine-induced increase in horizontal and vertical activity. Senktide alone induced a short-lasting increase in activity that was not accompanied by any alterations of the neurochemical parameters. In conditioned place preference (CPP) experiments, senktide pretreatment did not alter CPP induced by cocaine (5 and 10 mg/kg i.p.), and had no effect when given alone. Likewise, cocaine-conditioned locomotor activity was not affected by the NK(3)-R agonist. However, as in the microdialysis studies, cocaine-induced (5 and 10 mg/kg i.p.) hyperactivity was potentiated by senktide, and there was evidence for a facilitation of sensitization to the hyperlocomotor effects of cocaine by senktide. These data provide evidence that NK(3)-Rs are involved in the control of the hyperlocomotor and NAc DA response to cocaine, but not in cocaine-induced CPP.